Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

In vitro evaluation of hepatic transporter-mediated clinical drug-drug interactions: hepatocyte model optimization and retrospective investigation.

Bi YA, Kimoto E, Sevidal S, Jones HM, Barton HA, Kempshall S, Whalen KM, Zhang H, Ji C, Fenner KS, El-Kattan AF, Lai Y.

Drug Metab Dispos. 2012 Jun;40(6):1085-92. doi: 10.1124/dmd.111.043489. Epub 2012 Mar 1. Review.

PMID:
22381335
2.

Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data.

Jones HM, Barton HA, Lai Y, Bi YA, Kimoto E, Kempshall S, Tate SC, El-Kattan A, Houston JB, Galetin A, Fenner KS.

Drug Metab Dispos. 2012 May;40(5):1007-17. doi: 10.1124/dmd.111.042994. Epub 2012 Feb 16.

PMID:
22344703
3.

The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance.

Fenner KS, Jones HM, Ullah M, Kempshall S, Dickins M, Lai Y, Morgan P, Barton HA.

Xenobiotica. 2012 Jan;42(1):28-45. doi: 10.3109/00498254.2011.626464. Epub 2011 Nov 11. Review.

PMID:
22077101
4.

Case studies addressing human pharmacokinetic uncertainty using a combination of pharmacokinetic simulation and alternative first in human paradigms.

Harrison A, Gardner I, Hay T, Dickins M, Beaumont K, Phipps A, Purkins L, Allan G, Christian R, Duckworth J, Gurrell I, Kempshall S, Savage M, Seymour M, Simpson M, Taylor L, Turnpenny P.

Xenobiotica. 2012 Jan;42(1):57-74. doi: 10.3109/00498254.2011.622418. Epub 2011 Oct 12.

PMID:
21992032
5.

Full efficacy with no CNS side-effects: unachievable panacea or reality? DMPK considerations in design of drugs with limited brain penetration.

Cole S, Bagal S, El-Kattan A, Fenner K, Hay T, Kempshall S, Lunn G, Varma M, Stupple P, Speed W.

Xenobiotica. 2012 Jan;42(1):11-27. doi: 10.3109/00498254.2011.617847. Epub 2011 Oct 4. Review.

PMID:
21970687
6.

Development of a new permeability assay using low-efflux MDCKII cells.

Di L, Whitney-Pickett C, Umland JP, Zhang H, Zhang X, Gebhard DF, Lai Y, Federico JJ 3rd, Davidson RE, Smith R, Reyner EL, Lee C, Feng B, Rotter C, Varma MV, Kempshall S, Fenner K, El-Kattan AF, Liston TE, Troutman MD.

J Pharm Sci. 2011 Nov;100(11):4974-85. doi: 10.1002/jps.22674. Epub 2011 Jul 15.

PMID:
21766308
7.

A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder.

Callegari E, Malhotra B, Bungay PJ, Webster R, Fenner KS, Kempshall S, LaPerle JL, Michel MC, Kay GG.

Br J Clin Pharmacol. 2011 Aug;72(2):235-46. doi: 10.1111/j.1365-2125.2011.03961.x.

8.

Investigation into UDP-glucuronosyltransferase (UGT) enzyme kinetics of imidazole- and triazole-containing antifungal drugs in human liver microsomes and recombinant UGT enzymes.

Bourcier K, Hyland R, Kempshall S, Jones R, Maximilien J, Irvine N, Jones B.

Drug Metab Dispos. 2010 Jun;38(6):923-9. doi: 10.1124/dmd.109.030676. Epub 2010 Mar 19.

PMID:
20304965
9.

Excretion and metabolism of lersivirine (5-{[3,5-diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile), a next-generation non-nucleoside reverse transcriptase inhibitor, after administration of [14C]Lersivirine to healthy volunteers.

Vourvahis M, Gleave M, Nedderman AN, Hyland R, Gardner I, Howard M, Kempshall S, Collins C, LaBadie R.

Drug Metab Dispos. 2010 May;38(5):789-800. doi: 10.1124/dmd.109.031252. Epub 2010 Feb 2.

PMID:
20124396
10.

Refining the in vitro and in vivo critical parameters for P-glycoprotein, [I]/IC50 and [I2]/IC50, that allow for the exclusion of drug candidates from clinical digoxin interaction studies.

Cook JA, Feng B, Fenner KS, Kempshall S, Liu R, Rotter C, Smith DA, Troutman MD, Ullah M, Lee CA.

Mol Pharm. 2010 Apr 5;7(2):398-411. doi: 10.1021/mp900174z.

PMID:
20025245
11.

N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a "chemical knock-out equivalent" to assess the impact of efflux transporters on oral drug absorption in the rat.

Kalgutkar AS, Frederick KS, Chupka J, Feng B, Kempshall S, Mireles RJ, Fenner KS, Troutman MD.

J Pharm Sci. 2009 Dec;98(12):4914-27. doi: 10.1002/jps.21756.

PMID:
19373887
12.

In vitro and in vivo glucuronidation of midazolam in humans.

Hyland R, Osborne T, Payne A, Kempshall S, Logan YR, Ezzeddine K, Jones B.

Br J Clin Pharmacol. 2009 Apr;67(4):445-54. doi: 10.1111/j.1365-2125.2009.03386.x.

13.

Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug.

Fenner KS, Troutman MD, Kempshall S, Cook JA, Ware JA, Smith DA, Lee CA.

Clin Pharmacol Ther. 2009 Feb;85(2):173-81. doi: 10.1038/clpt.2008.195. Epub 2008 Nov 5.

PMID:
18987624
14.

Activation of the interleukin 2 receptor: a possible role for tyrosine phosphatases.

Ellery JM, Kempshall SJ, Nicholls PJ.

Cell Signal. 2000 Jun;12(6):367-73. Review.

PMID:
10889465

Supplemental Content

Loading ...
Support Center